[Immunoenzyme technique for analysis of cystatin C in serum of patients with hemoblastosis].
Cystatin C is a low-molecular endogenous inhibitor of cysteic proteinases. Sets for immune-enzyme assay of cystatin C in human blood serum (KRKK, Slovenia) were made used of in the case study. The concentration of cystatin C (CCC) in blood serum was found to be higher in cases of certain hemoblastoses (Non-Hodgkin's disease, lymphogranulomatosis and multiple myeloma), with the highest concentration of the inhibitor being observed in patients with resistance to the conducted polychemotherapy and a poor prognostication. The treatment of Non-Hodgkin's disease and of lymphogranulomatosis brought about a normalized CCC in blood serum. It was suggested that CCC in blood serum reflects a nature of tumor growth and, obviously, it can be a criterion in assessing the therapy efficiency. The concentration of alpha 1-proteinases inhibitor remained unchanged before and after treatment.
Poteriaeva
O N
ON
Usova
T A
TA
Levina
O A
OA
Iarygina
E S
ES
Korolenko
T A
TA
D000208:Acute Disease; D000307:Adrenal Gland Diseases / Q000097:blood / Q000188:drug therapy; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D055316:Cystatin C; D015891:Cystatins / Q000097:blood*; D019008:Drug Resistance, Neoplasm; D019337:Hematologic Neoplasms / Q000097:blood* / Q000188:drug therapy; D006689:Hodgkin Disease / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007124:Immunoenzyme Techniques; D007938:Leukemia / Q000097:blood / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000097:blood / Q000188:drug therapy; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; C525030:CST3 protein, human; D055316:Cystatin C; D015891:Cystatins